Tobacco use is the leading cause of preventable disease, disability, and death in the United States, according to the CDC, and the same is true for many developed countries. About 40 million Americans still smoke cigarettes and nearly a half a million Americans die prematurely of smoking or exposure to secondhand smoke every year. These trends have given rise to a large and growing smoking cessation industry that could be worth upwards of $20 billion.
Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX), developer of the DehyraTECH™ platform for improving the bioavailability of active pharmaceutical ingredients (APIs), recently unveiled positive results from its trials involving nicotine, which could pave the way for its entry into the large and growing nicotine replacement industry.
A Large & Growing Market
Smoking may be on the decline across many developed countries, but addiction is rapidly increasing in emerging markets. A growing body of evidence has shown that smoking causes diseases like chronic obstructive pulmonary disease (COPD), asthma, cardiac diseases, and lung cancer, which translates to a high mortality rate. These trends have led to strong demand for innovative nicotine replacement therapy products to help smokers kick the habit.
According to Grand View Market Research, the smoking cessation and nicotine de-addiction market is projected to reach $21.8 billion in size by 2024. These products include nicotine chewing gums and transdermal patches, as well as e-cigarettes, which are projected to see a 19 percent compound annual growth rate over the forecast period. North America represents the largest market with a 35 percent share, but the Asia-Pacific region is the fastest growing market.
There are many different public companies active in the space, including Pfizer Inc. (PFE), GlaxoSmithKline plc (GSK), and Imperial Tobacco Ltd. (IMBBY), which have developed established gum and patch products. Smaller companies have been largely active in the
Emblem Corp. (TSXV:EMC) (EMC.WT) (“Emblem” or the “Company”), is pleased to announce that it has purchased C$2.5 million of units (“Units”) of Fire & Flower Inc. (“Fire & Flower”) at a price of C$0.80 per Unit (the “Subscription”) as part of a larger Unit offering conducted by Fire & Flower. Each Unit consists of one common share in the capital of Fire & Flower (each, a “Fire & Flower Share”) and one common share purchase warrant entitling the holder thereof to acquire one (1) additional Fire & Flower Share at a price of C$1.05 per share for a period of two (2) years, subject to adjustments in certain events. Nick Dean, CEO of Emblem, says “Our partnership with Fire & Flower reinforces our belief that access to the end consumer is critical for driving long-term shareholder value. In a highly regulated environment, retail will be the front-line for customer education, driving … Continue reading
President Trump’s unexpected support for state-level cannabis legalization has spurred Democrats to rally behind new legislation for federal legalization over the past weeks. Senator Cory Booker (D-NJ) introduced the Marijuana Justice Act last year to remove cannabis from the Controlled Substances Act, incentivize states to mitigate racial disparities in marijuana arrests, and expunge federal convictions specific to marijuana possession. Last week, Senator Bernie Sanders (I-VT), who rose to fame during the last presidential election as a Democratic contender to Hillary Clinton, signed on as a co-sponsor of the legislation. “Here is the simple truth: Blacks and whites have similar rates of marijuana use, but black people are far more likely to be arrested for it. Last year, about 600,000 people were arrested for possession of marijuana. Many of those people, disproportionately people of color, have seen their lives destroyed because they have criminal records as a result of marijuana use. … Continue reading
As both recreational and medicinal marijuana become increasingly legal across the United States, the way people ingest cannabis is becoming increasingly creative. No longer are cannabis enthusiasts confined to consuming the flower alone. These days, there’s wax, shatter, sugar, budder, and an ever-growing range of other cannabis concentrates that can be consumed in lieu of smoking the plant. Making these concentrates is an art all its own as there are quite a few different ways THC can be extracted from the plant to produce them. If you’re curious about making your own, then spend some time getting to know the pros and cons of three of the most popular methods of extraction. Butane Extraction Butane is a common method of extraction but it can also be a very dangerous one. Whether you’re extracting at home with basic equipment or you’re doing it in large scales, the process is essentially the same. … Continue reading
KELOWNA, BC / ACCESSWIRE / April 23, 2018 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the ”Company” or ”Lexaria”), a drug delivery platform innovator, is pleased to announce that it has commenced a clinical study in Europe to evaluate the cardiovascular and cognitive health effects of Lexaria’s high absorption TurboCBD™ capsules. The pharmacokinetic and pharmacodynamic data generated by this study will provide objective human performance findings that will assist in the development of the Company’s next-generation cannabinoid product formulations and be of significant benefit to the Company and its partners. The study employs a double-blind and placebo-controlled cross-over design measuring TurboCBD™ effects both after a single 45mg dose and, on a separate day, after a single 90mg dose in 12 healthy male volunteers. The study hypothesises that, following TurboCBD™ supplementation, circulating CBD and nitric oxide will increase in most participants; that glucose and blood pressure will remain stable; and that vascular function, … Continue reading
TORONTO, April 23, 2018 (GLOBE NEWSWIRE) — Maricann Group Inc. (CSE:MARI)(FRANKFURT:75M)(OTCQB:MRRCF)(“Maricann” or the “Company”), is pleased to announce that it has received all of the necessary approvals from Health Canada to commence cultivation in Phase One of the Company’s new, state-of-the-art grow facility in Langton, Ontario, Canada. This is Maricann’s third licence issued by Health Canada. “The licensing of Phase One of our Canadian expansion is a major milestone for both our employees and shareholders. This facility could be built in the Arctic, or the equator and still replicate the exact same cannabis every time. Due to the control and automation platform, combined with a unique building envelope design from standard stock, pre-engineered steel and greenhouse components, our overall costs are reduced,” stated Ben Ward, CEO The design of the facility is revolutionary, combining the best of indoor cultivation and greenhouse technology. We utilize natural sunlight in a completely controlled, … Continue reading
Vancouver, BC – April 20, 2018 – Choom™ (CSE: CHOO; OTCQB: CHOOF) (the “Company” or “Choom”), is taking a look ahead at the forecast for the legal recreational industry, and gives the weather forecast for 4/20: Blue skies ahead. With a hint of green. Choom’s CEO Chris Bogart comments: “Expected legalization this summer is just around the corner, and while some might think they have seen the crest of cannabis wave that has been building for years, Choom recognizes that we’ve just started paddling into a wave that will only build momentum once legalization is in place. In every major market, Colorado, Washington, California, we’ve seen adult-use grow year over year by double digits. Choom sees the same growth potential in a legal adult-use market for Canada as just the beginning.” UPDATE: THE START OF A GREEN SWELL STRATEGY: Choom™ was created specifically for the Canadian recreational market with a strategy … Continue reading
The cannabis industry is rapidly growing across North America and around the world, but many cultivators are still using antiquated growing techniques. As these cultivators look to increase production, they’re increasingly looking at strategies like micropropagation (tissue culture) as a way to efficiently scale up their operations, reduce costs, and most importantly reduce the risk of crop failures due to pathogens. At the core of this trend is Segra International Corp., which has become a leader in cannabis micropropagation. The company plans to go public later in 2018. Click here to receive Segra International updates prior to the company going public. CFN Media recently interviewed the company’s CEO, Todd McMurray, to discuss its strategy in the space and what sets it apart from the competition. Why Micropropagation Matters Many cannabis cultivators use traditional cloning methods to produce genetically-identical strains. By cutting a healthy lower branch, placing it immediately into water, and … Continue reading
VANCOUVER, April 19, 2018 /CNW/ – Speakeasy Cannabis Club Ltd. (CSE: EASY) (Frankfurt: 39H) (the “Company”) is pleased to announce an update on its application with Health Canada to obtain licensed producer status under the Access to Cannabis for Medical Purposes Regulations. The Company has submitted its extensive evidence package on its fully completed 10,000-square-foot facility to Health Canada. Health Canada has acknowledged receipt and is currently reviewing the file. This is the final step in order to obtain a production licence under Section 35 of the ACMPR (access to cannabis for medical purposes regulations). This package included documentation, detailed photos and video, facility design packages and the ability to demonstrate product storage, security, monitoring of access and record keeping. No assurances can be given at this point on the time frame for inspection and potential subsequent granting of licensed producer status. Speakeasy is also pleased to announce that it has commenced construction on … Continue reading
Toronto, Ontario–(Newsfile Corp. – April 19, 2018) – RISE Life Science Corp. (CSE: RLSC) (formerly Luminor Medical Technologies Inc. (the “Company” or “RISE”) is pleased to announce that, further to it press release dated March 29, 2018, it has closed tranches (each a “Tranche”) of its previously announced non-brokered private placement (the “Offering”) through the issuance of an aggregate of 7,366,166 units (each a “Unit”) at a price of $0.30 per Unit for gross proceeds of $2,209,849.80. Each Unit is comprised of one common share (“Common Share”) of the Company and one-half of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share for a period of twenty-four (24) months from the date of closing of the Tranche at a price of $0.45 per Common Share. The proceeds of the Offering will be used for general working capital purposes. The Company … Continue reading